{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T07:15:23Z","timestamp":1779002123903,"version":"3.51.4"},"reference-count":169,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T00:00:00Z","timestamp":1611532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T00:00:00Z","timestamp":1611532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Bacillus Calmette\u2013Gu\u00e9rin (BCG), the only vaccine proven to be effective against tuberculosis (TB), is the most commonly used vaccine globally. In addition to its effects on mycobacterial diseases, an increasing amount of epidemiological and experimental evidence accumulated since its introduction in 1921 has shown that BCG also exerts non-specific effects against a number of diseases, such as non-mycobacterial infections, allergies and certain malignancies. Recent Corona Virus Disease 2019 (COVID-19) outbreak has put BCG, a classic vaccine with significant non-specific protection, into the spotlight again. This literature review briefly covers the diverse facets of BCG vaccine, providing new perspectives in terms of specific and non-specific protection mechanisms of this old, multifaceted, and controversial vaccine.<\/jats:p>","DOI":"10.1038\/s41541-020-00278-0","type":"journal-article","created":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T11:06:41Z","timestamp":1611572801000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["The double-sided effects of Mycobacterium Bovis bacillus Calmette\u2013Gu\u00e9rin vaccine"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5542-3375","authenticated-orcid":false,"given":"Junli","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingjun","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6261-1232","authenticated-orcid":false,"given":"Chuan","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,25]]},"reference":[{"key":"278_CR1","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1016\/j.rmed.2006.08.006","volume":"100","author":"TM Daniel","year":"2006","unstructured":"Daniel, T. M. The history of tuberculosis. Respir. Med. 100, 1862\u20131870 (2006).","journal-title":"Respir. Med."},{"key":"278_CR2","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1016\/j.vaccine.2004.01.050","volume":"22","author":"MJ Corbel","year":"2004","unstructured":"Corbel, M. J., Fruth, U., Griffiths, E. & Knezevic, I. Report on a WHO consultation on the characterisation of BCG strains, Imperial College, London 15-16 December 2003. Vaccine 22, 2675\u20132680 (2004).","journal-title":"Vaccine"},{"key":"278_CR3","volume-title":"Global tuberculosis report 2018","author":"WHO. World Health Organization.","year":"2018","unstructured":"WHO. World Health Organization. Global tuberculosis report 2018. (WHO, Geneva, 2018)."},{"key":"278_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002607","volume":"8","author":"TH Ottenhoff","year":"2012","unstructured":"Ottenhoff, T. H. & Kaufmann, S. H. Vaccines against tuberculosis: where are we and where do we need to go? PLoS Pathog. 8, e1002607 (2012).","journal-title":"PLoS Pathog."},{"key":"278_CR5","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1098\/rstb.2011.0097","volume":"366","author":"H McShane","year":"2011","unstructured":"McShane, H. Tuberculosis vaccines: beyond bacille Calmette-Guerin. Philos. Trans. R. Soc. Lond. Ser. B, Biol. Sci. 366, 2782\u20132789 (2011).","journal-title":"Philos. Trans. R. Soc. Lond. Ser. B, Biol. Sci."},{"key":"278_CR6","doi-asserted-by":"publisher","first-page":"5596","DOI":"10.1073\/pnas.0700869104","volume":"104","author":"R Brosch","year":"2007","unstructured":"Brosch, R. et al. Genome plasticity of BCG and impact on vaccine efficacy. Proc. Natl. Acad. Sci. USA 104, 5596\u20135601 (2007).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"278_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032567","volume":"7","author":"M Favorov","year":"2012","unstructured":"Favorov, M. et al. Comparative tuberculosis (TB) prevention effectiveness in children of Bacillus Calmette-Guerin (BCG) vaccines from different sources, Kazakhstan. PloS ONE 7, e32567 (2012).","journal-title":"PloS ONE"},{"key":"278_CR8","doi-asserted-by":"publisher","first-page":"4270","DOI":"10.1016\/S0264-410X(03)00484-5","volume":"21","author":"S Mostowy","year":"2003","unstructured":"Mostowy, S., Tsolaki, A. G., Small, P. M. & Behr, M. A. The in vitro evolution of BCG vaccines. Vaccine 21, 4270\u20134274 (2003).","journal-title":"Vaccine"},{"key":"278_CR9","unstructured":"WHO. V3P database (Data 2017). Available at http:\/\/www.who.int\/immunization\/programmes_systems\/procurement\/v3p\/platform\/en\/. Accessed Nov 2017."},{"key":"278_CR10","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s10096-020-03843-6","volume":"39","author":"J Li","year":"2020","unstructured":"Li, J. et al. Tuberculosis vaccine development: from classic to clinical candidates. Eur. J. Clin. Microbiol. Infect. Dis. 39, 1405\u20131425 (2020).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"278_CR11","doi-asserted-by":"publisher","first-page":"532","DOI":"10.3389\/fimmu.2018.00532","volume":"9","author":"E Whittaker","year":"2018","unstructured":"Whittaker, E., Goldblatt, D., McIntyre, P. & Levy, O. Neonatal immunization: rationale, current state, and future prospects. Front. Immunol. 9, 532 (2018).","journal-title":"Front. Immunol."},{"key":"278_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1542\/peds.96.1.29","volume":"96","author":"GA Colditz","year":"1995","unstructured":"Colditz, G. A. et al. The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 96, 29\u201335 (1995).","journal-title":"Pediatrics"},{"key":"278_CR13","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1093\/ije\/17.3.629","volume":"17","author":"I Miceli","year":"1988","unstructured":"Miceli, I. et al. Evaluation of the effectiveness of BCG vaccination using the case-control method in Buenos Aires, Argentina. Int. J. Epidemiol. 17, 629\u2013634 (1988).","journal-title":"Int. J. Epidemiol."},{"key":"278_CR14","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/S0140-6736(06)68507-3","volume":"367","author":"BB Trunz","year":"2006","unstructured":"Trunz, B. B., Fine, P. & Dye, C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet (Lond., Engl.) 367, 1173\u20131180 (2006).","journal-title":"Lancet (Lond., Engl.)"},{"key":"278_CR15","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1016\/j.vaccine.2005.12.044","volume":"24","author":"E Bonifachich","year":"2006","unstructured":"Bonifachich, E. et al. Protective effect of Bacillus Calmette-Guerin (BCG) vaccination in children with extra-pulmonary tuberculosis, but not the pulmonary disease. A case-control study in Rosario, Argentina. Vaccine 24, 2894\u20132899 (2006).","journal-title":"Vaccine"},{"key":"278_CR16","first-page":"g4643","volume":"349","author":"A Roy","year":"2014","unstructured":"Roy, A. et al. Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis. BMJ (Clin. Res. ed.) 349, g4643 (2014).","journal-title":"BMJ (Clin. Res. ed.)"},{"key":"278_CR17","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/infdis\/jir240","volume":"204","author":"P Aaby","year":"2011","unstructured":"Aaby, P. et al. Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period? J. Infect. Dis. 204, 245\u2013252 (2011).","journal-title":"J. Infect. Dis."},{"key":"278_CR18","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/INF.0b013e3182458289","volume":"31","author":"S Biering-S\u00f8rensen","year":"2012","unstructured":"Biering-S\u00f8rensen, S. et al. Small randomized trial among low-birth-weight children receiving bacillus Calmette-Gu\u00e9rin vaccination at first health center contact. Pediatr. Infect. Dis. J. 31, 306\u2013308 (2012).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"278_CR19","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1097\/01.inf.0000129693.81082.a0","volume":"23","author":"A Roth","year":"2004","unstructured":"Roth, A. et al. Low birth weight infants and Calmette-Gu\u00e9rin bacillus vaccination at birth: community study from Guinea-Bissau. Pediatr. Infect. Dis. J. 23, 544\u2013550 (2004).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"278_CR20","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1093\/cid\/cix525","volume":"65","author":"S Biering-S\u00f8rensen","year":"2017","unstructured":"Biering-S\u00f8rensen, S. et al. Early BCG-Denmark and neonatal mortality among infants weighing <2500\u2009g: a randomized Controlled Trial. Clin. Infect. Dis. 65, 1183\u20131190 (2017).","journal-title":"Clin. Infect. Dis."},{"key":"278_CR21","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.vaccine.2004.09.006","volume":"23","author":"LG Stensballe","year":"2005","unstructured":"Stensballe, L. G. et al. Acute lower respiratory tract infections and respiratory syncytial virus in infants in Guinea-Bissau: a beneficial effect of BCG vaccination for girls community based case-control study. Vaccine 23, 1251\u20131257 (2005).","journal-title":"Vaccine"},{"key":"278_CR22","first-page":"185","volume":"43","author":"Rifai Wardhana","year":"2011","unstructured":"Wardhana, Rifai, Datau, E. A., Sultana, A., Mandang, V. V. & Jim, E. The efficacy of Bacillus Calmette-Guerin vaccinations for the prevention of acute upper respiratory tract infection in the elderly. Acta Med. Indonesiana 43, 185\u2013190 (2011).","journal-title":"Acta Med. Indonesiana"},{"key":"278_CR23","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/j.1525-1470.2012.01848.x","volume":"30","author":"A Salem","year":"2013","unstructured":"Salem, A., Nofal, A. & Hosny, D. Treatment of common and plane warts in children with topical viable Bacillus Calmette-Guerin. Pediatr. Dermatol. 30, 60\u201363 (2013).","journal-title":"Pediatr. Dermatol."},{"key":"278_CR24","doi-asserted-by":"publisher","first-page":"411","DOI":"10.4103\/0378-6323.193623","volume":"83","author":"I Podder","year":"2017","unstructured":"Podder, I. et al. Immunotherapy in viral warts with intradermal Bacillus Calmette-Guerin vaccine versus intradermal tuberculin purified protein derivative: a double-blind, randomized controlled trial comparing effectiveness and safety in a tertiary care center in Eastern India. Indian J. Dermatol. Venereol. Leprol. 83, 411 (2017).","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"278_CR25","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/dth.12336","volume":"29","author":"D Daulatabad","year":"2016","unstructured":"Daulatabad, D., Pandhi, D. & Singal, A. BCG vaccine for immunotherapy in warts: is it really safe in a tuberculosis endemic area? Dermatol. Ther. 29, 168\u2013172 (2016).","journal-title":"Dermatol. Ther."},{"key":"278_CR26","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/j.cmi.2019.04.020","volume":"25","author":"S Moorlag","year":"2019","unstructured":"Moorlag, S., Arts, R. J. W., van Crevel, R. & Netea, M. G. Non-specific effects of BCG vaccine on viral infections. Clin. Microbiol. Infect. 25, 1473\u20131478 (2019).","journal-title":"Clin. Microbiol. Infect."},{"key":"278_CR27","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/infdis\/136.2.171","volume":"136","author":"JC Spencer","year":"1977","unstructured":"Spencer, J. C., Ganguly, R. & Waldman, R. H. Nonspecific protection of mice against influenza virus infection by local or systemic immunization with Bacille Calmette-Gu\u00e9rin. J. Infect. Dis. 136, 171\u2013175 (1977).","journal-title":"J. Infect. Dis."},{"key":"278_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0180143","volume":"12","author":"S Mukherjee","year":"2017","unstructured":"Mukherjee, S. et al. Boosting efferocytosis in alveolar space using BCG vaccine to protect host against influenza pneumonia. PloS ONE 12, e0180143 (2017).","journal-title":"PloS ONE"},{"key":"278_CR29","first-page":"173","volume":"127","author":"F Floc\u2019h","year":"1976","unstructured":"Floc\u2019h, F. & Werner, G. H. Increased resistance to virus infections of mice inoculated with BCG (Bacillus calmette-gu\u00e9rin). Ann. Immunol. 127, 173\u2013186 (1976).","journal-title":"Ann. Immunol."},{"key":"278_CR30","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3181\/00379727-152-39327","volume":"152","author":"SE Starr","year":"1976","unstructured":"Starr, S. E., Visintine, A. M., Tomeh, M. O. & Nahmias, A. J. Effects of immunostimulants on resistance of newborn mice to herpes simplex type 2 infection. Proc. Soc. Exp. Biol. Med. 152, 57\u201360 (1976).","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"278_CR31","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/0166-3542(85)90025-7","volume":"5","author":"S Ikeda","year":"1985","unstructured":"Ikeda, S., Negishi, T. & Nishimura, C. Enhancement of non-specific resistance to viral infection by muramyldipeptide and its analogs. Antivir. Res. 5, 207\u2013215 (1985).","journal-title":"Antivir. Res."},{"key":"278_CR32","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/0264-410X(87)90155-1","volume":"5","author":"C Ishihara","year":"1987","unstructured":"Ishihara, C. et al. Suppression of Sendai virus growth by treatment with N alpha-acetylmuramyl-L-alanyl-D-isoglutaminyl-N epsilon-stearoyl-L-lysine in mice. Vaccine 5, 295\u2013301 (1987).","journal-title":"Vaccine"},{"key":"278_CR33","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1159\/000452171","volume":"23","author":"S Kulkarni","year":"2016","unstructured":"Kulkarni, S. et al. Bacillus Calmette-Gu\u00e9rin confers neuroprotection in a murine model of Japanese Encephalitis. Neuroimmunomodulation 23, 278\u2013286 (2016).","journal-title":"Neuroimmunomodulation"},{"key":"278_CR34","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1128\/iai.19.1.225-230.1978","volume":"19","author":"DL Lodmell","year":"1978","unstructured":"Lodmell, D. L. & Ewalt, L. C. Enhanced resistance against encephalomyocarditis virus infection in mice, induced by a nonviable Mycobacterium tuberculosis oil-droplet vaccine. Infect. Immun. 19, 225\u2013230 (1978).","journal-title":"Infect. Immun."},{"key":"278_CR35","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1128\/iai.22.3.740-745.1978","volume":"22","author":"DL Lodmell","year":"1978","unstructured":"Lodmell, D. L. & Ewalt, L. C. Induction of enhanced resistance against encephalomyocarditis virus infection of mice by nonviable Mycobacterium tuberculosis: mechanisms of protection. Infect. Immun. 22, 740\u2013745 (1978).","journal-title":"Infect. Immun."},{"key":"278_CR36","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1128\/iai.20.1.312-314.1978","volume":"20","author":"T Suenaga","year":"1978","unstructured":"Suenaga, T., Okuyama, T., Yoshida, I. & Azuma, M. Effect of Mycobacterium tuberculosis BCG infection on the resistance of mice to ectromelia virus infection: participation of interferon in enhanced resistance. Infect. Immun. 20, 312\u2013314 (1978).","journal-title":"Infect. Immun."},{"key":"278_CR37","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1128\/iai.42.2.567-573.1983","volume":"42","author":"T Sakuma","year":"1983","unstructured":"Sakuma, T., Suenaga, T., Yoshida, I. & Azuma, M. Mechanisms of enhanced resistance of Mycobacterium bovis BCG-treated mice to ectromelia virus infection. Infect. Immun. 42, 567\u2013573 (1983).","journal-title":"Infect. Immun."},{"key":"278_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-16067-0","volume":"7","author":"ME Morra","year":"2017","unstructured":"Morra, M. E. et al. Early vaccination protects against childhood leukemia: a systematic review and meta-analysis. Sci. Rep. 7, 15986 (2017).","journal-title":"Sci. Rep."},{"key":"278_CR39","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/all.13314","volume":"73","author":"LM Th\u00f8stesen","year":"2018","unstructured":"Th\u00f8stesen, L. M. et al. Neonatal BCG vaccination and atopic dermatitis before 13 months of age: a randomized clinical trial. Allergy 73, 498\u2013504 (2018).","journal-title":"Allergy"},{"key":"278_CR40","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/ppe.12263","volume":"30","author":"MC Rousseau","year":"2016","unstructured":"Rousseau, M. C., El-Zein, M., Conus, F., Legault, L. & Parent, M. E. Bacillus Calmette-Gu\u00e9rin (BCG) vaccination in infancy and risk of childhood diabetes. Paediatr. Perinat. Epidemiol. 30, 141\u2013148 (2016).","journal-title":"Paediatr. Perinat. Epidemiol."},{"key":"278_CR41","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1093\/infdis\/172.3.698","volume":"172","author":"GJ Fennelly","year":"1995","unstructured":"Fennelly, G. J., Flynn, J. L., ter Meulen, V., Liebert, U. G. & Bloom, B. R. Recombinant bacille Calmette-Gu\u00e9rin priming against measles. J. Infect. Dis. 172, 698\u2013705 (1995).","journal-title":"J. Infect. Dis."},{"key":"278_CR42","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1128\/CVI.00407-06","volume":"14","author":"JS Yu","year":"2007","unstructured":"Yu, J. S. et al. Recombinant Mycobacterium bovis bacillus Calmette-Guerin elicits human immunodeficiency virus type 1 envelope-specific T lymphocytes at mucosal sites. Clin. Vaccine Immunol. 14, 886\u2013893 (2007).","journal-title":"Clin. Vaccine Immunol."},{"key":"278_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0071601","volume":"8","author":"R Chapman","year":"2013","unstructured":"Chapman, R., Stutz, H., Jacobs, W. Jr., Shephard, E. & Williamson, A. L. Priming with recombinant auxotrophic BCG expressing HIV-1 Gag, RT and Gp120 and boosting with recombinant MVA induces a robust T cell response in mice. PloS ONE 8, e71601 (2013).","journal-title":"PloS ONE"},{"key":"278_CR44","doi-asserted-by":"publisher","first-page":"214","DOI":"10.4049\/jimmunol.1300118","volume":"192","author":"CE Palavecino","year":"2014","unstructured":"Palavecino, C. E., C\u00e9spedes, P. F., G\u00f3mez, R. S., Kalergis, A. M. & Bueno, S. M. Immunization with a recombinant bacillus Calmette-Guerin strain confers protective Th1 immunity against the human metapneumovirus. J. Immunol. 192, 214\u2013223 (2014).","journal-title":"J. Immunol."},{"key":"278_CR45","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.3389\/fimmu.2018.02875","volume":"9","author":"JA Soto","year":"2018","unstructured":"Soto, J. A. et al. Recombinant BCG vaccines reduce pneumovirus-caused airway pathology by inducing protective humoral immunity. Front. Immunol. 9, 2875 (2018).","journal-title":"Front. Immunol."},{"key":"278_CR46","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1046\/j.1523-1747.2002.00643.x","volume":"119","author":"A Pfahlberg","year":"2002","unstructured":"Pfahlberg, A. et al. Inverse association between melanoma and previous vaccinations against tuberculosis and smallpox: results of the FEBIM study. J. invest. Dermatol. 119, 570\u2013575 (2002).","journal-title":"J. invest. Dermatol."},{"key":"278_CR47","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1046\/j.1442-2042.2002.00415.x","volume":"9","author":"N Ikeda","year":"2002","unstructured":"Ikeda, N., Toida, I., Iwasaki, A., Kawai, K. & Akaza, H. Surface antigen expression on bladder tumor cells induced by bacillus Calmette-Gu\u00e9rin (BCG): A role of BCG internalization into tumor cells. Int. J. Urol. 9, 29\u201335 (2002).","journal-title":"Int. J. Urol."},{"key":"278_CR48","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.tube.2007.11.010","volume":"88","author":"D Murphy","year":"2008","unstructured":"Murphy, D., Corner, L. A. & Gormley, E. Adverse reactions to Mycobacterium bovis bacille Calmette-Gu\u00e9rin (BCG) vaccination against tuberculosis in humans, veterinary animals and wildlife species. Tuberculosis (Edinb., Scotl.) 88, 344\u2013357 (2008).","journal-title":"Tuberculosis (Edinb., Scotl.)"},{"key":"278_CR49","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1136\/adc.2005.078972","volume":"91","author":"T Bolger","year":"2006","unstructured":"Bolger, T., O\u2019Connell, M., Menon, A. & Butler, K. Complications associated with the bacille Calmette-Gu\u00e9rin vaccination in Ireland. Arch. Dis. Child. 91, 594\u2013597 (2006).","journal-title":"Arch. Dis. Child."},{"key":"278_CR50","first-page":"66","volume":"18","author":"KK Govindarajan","year":"2011","unstructured":"Govindarajan, K. K. & Chai, F. Y. BCG adenitis-need for increased awareness. Malays. J. Med. Sci. 18, 66\u201369 (2011).","journal-title":"Malays. J. Med. Sci."},{"key":"278_CR51","first-page":"133","volume":"5","author":"S Afshar Paiman","year":"2006","unstructured":"Afshar Paiman, S., Siadati, A., Mamishi, S., Tabatabaie, P. & Khotaee, G. Disseminated Mycobacterium bovis infection after BCG vaccination. Iran. J. Allergy Asthma Immunol. 5, 133\u2013137 (2006).","journal-title":"Iran. J. Allergy Asthma Immunol."},{"key":"278_CR52","first-page":"48","volume":"7","author":"R Barari-Savadkouhi","year":"2016","unstructured":"Barari-Savadkouhi, R., Shour, A. & Masrour-Roudsari, J. A study of the incidence of BCG vaccine complications in infants of Babol, Mazandaran (2011-2013). Casp. J. Intern. Med. 7, 48\u201351 (2016).","journal-title":"Casp. J. Intern. Med."},{"key":"278_CR53","doi-asserted-by":"publisher","first-page":"5470","DOI":"10.1016\/j.vaccine.2015.07.103","volume":"33","author":"A Venkataraman","year":"2015","unstructured":"Venkataraman, A., Yusuff, M., Liebeschuetz, S., Riddell, A. & Prendergast, A. J. Management and outcome of Bacille Calmette-Gu\u00e9rin vaccine adverse reactions. Vaccine 33, 5470\u20135474 (2015).","journal-title":"Vaccine"},{"key":"278_CR54","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1111\/j.1365-2230.2006.02083.x","volume":"31","author":"J Muto","year":"2006","unstructured":"Muto, J., Kuroda, K. & Tajima, S. Papular tuberculides post-BCG vaccination: case report and review of the literature in Japan. Clin. Exp. Dermatol. 31, 611\u2013612 (2006).","journal-title":"Clin. Exp. Dermatol."},{"key":"278_CR55","first-page":"223","volume":"16","author":"PK Chan","year":"2010","unstructured":"Chan, P. K., Ng, B. K. & Wong, C. Y. Bacille Calmette-Gu\u00e9rin osteomyelitis of the proximal femur. Hong. Kong Med. J. 16, 223\u2013226 (2010).","journal-title":"Hong. Kong Med. J."},{"key":"278_CR56","first-page":"291","volume":"3","author":"M Gharehdaghi","year":"2015","unstructured":"Gharehdaghi, M., Hassani, M., Ghodsi, E., Khooei, A. & Moayedpour, A. Bacille Calmette-Gu\u00e9rin osteomyelitis. Arch. Bone Jt. Surg. 3, 291\u2013295 (2015).","journal-title":"Arch. Bone Jt. Surg."},{"key":"278_CR57","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s10067-014-2842-5","volume":"35","author":"BY Atikan","year":"2016","unstructured":"Atikan, B. Y., Cavusoglu, C., Dortkardesler, M. & Sozeri, B. Assessment of tuberculosis infection during treatment with biologic agents in a BCG-vaccinated pediatric population. Clin. Rheumatol. 35, 427\u2013431 (2016).","journal-title":"Clin. Rheumatol."},{"key":"278_CR58","first-page":"47","volume":"63","author":"A Lotte","year":"1988","unstructured":"Lotte, A. et al. Second IUATLD study on complications induced by intradermal BCG-vaccination. Bull. Int. Union Tuberc. Lung Dis. 63, 47\u201359 (1988).","journal-title":"Bull. Int. Union Tuberc. Lung Dis."},{"key":"278_CR59","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.jaci.2014.02.028","volume":"133","author":"BE Marciano","year":"2014","unstructured":"Marciano, B. E. et al. BCG vaccination in patients with severe combined immunodeficiency: complications, risks, and vaccination policies. J. Allergy Clin. Immunol. 133, 1134\u20131141 (2014).","journal-title":"J. Allergy Clin. Immunol."},{"key":"278_CR60","doi-asserted-by":"publisher","first-page":"195","DOI":"10.7774\/cevr.2015.4.2.195","volume":"4","author":"S Mahmoudi","year":"2015","unstructured":"Mahmoudi, S. et al. Adverse reactions to Mycobacterium bovis bacille Calmette-Gu\u00e9rin vaccination against tuberculosis in Iranian children. Clin. Exp. Vaccine Res. 4, 195\u2013199 (2015).","journal-title":"Clin. Exp. Vaccine Res."},{"key":"278_CR61","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1093\/tropej\/fmt100","volume":"60","author":"M Daei Parizi","year":"2014","unstructured":"Daei Parizi, M., Kardoust Parizi, A. & Izadipour, S. Evaluating clinical course of BCG lymphadenitis and factors affect on it during a 5-year period in Kerman, Iran. J. Trop. Pediatr. 60, 148\u2013153 (2014).","journal-title":"J. Trop. Pediatr."},{"key":"278_CR62","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.aller.2014.01.003","volume":"43","author":"P Sharifi Asadi","year":"2015","unstructured":"Sharifi Asadi, P. et al. Clinical, laboratory and imaging findings of the patients with disseminated bacilli Calmette-Guerin disease. Allergol. Immunopathol. 43, 254\u2013258 (2015).","journal-title":"Allergol. Immunopathol."},{"key":"278_CR63","doi-asserted-by":"publisher","first-page":"202","DOI":"10.4103\/0377-4929.97869","volume":"55","author":"E Bukhari","year":"2012","unstructured":"Bukhari, E., Alzahrani, M., Alsubaie, S., Alrabiaah, A. & Alzamil, F. Bacillus Calmette-Guerin lymphadenitis: a 6-year experience in two Saudi hospitals. Indian J. Pathol. Microbiol. 55, 202\u2013205 (2012).","journal-title":"Indian J. Pathol. Microbiol."},{"key":"278_CR64","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1097\/00006454-199806000-00020","volume":"17","author":"N Kuyucu","year":"1998","unstructured":"Kuyucu, N., Kuyucu, S., Ocal, B. & Tezi\u00e7, T. Comparison of oral erythromycin, local administration of streptomycin and placebo therapy for nonsuppurative Bacillus Calmette-Gu\u00e9rin lymphadenitis. Pediatr. Infect. Dis. J. 17, 524\u2013525 (1998).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"278_CR65","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1097\/00006454-200205000-00026","volume":"21","author":"A Singla","year":"2002","unstructured":"Singla, A., Singh, S., Goraya, J. S., Radhika, S. & Sharma, M. The natural course of nonsuppurative Calmette-Gu\u00e9rin bacillus lymphadenitis. Pediatr. Infect. Dis. J. 21, 446\u2013448 (2002).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"278_CR66","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.3389\/fimmu.2017.01134","volume":"8","author":"HM Dockrell","year":"2017","unstructured":"Dockrell, H. M. & Smith, S. G. What have we learnt about BCG vaccination in the last 20 years? Front. Immunol. 8, 1134 (2017).","journal-title":"Front. Immunol."},{"key":"278_CR67","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3389\/fimmu.2017.00407","volume":"8","author":"JI Moliva","year":"2017","unstructured":"Moliva, J. I., Turner, J. & Torrelles, J. B. Immune responses to bacillus Calmette-Gu\u00e9rin vaccination: why do they fail to protect against Mycobacterium tuberculosis? Front. Immunol. 8, 407 (2017).","journal-title":"Front. Immunol."},{"key":"278_CR68","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.4049\/jimmunol.168.3.1294","volume":"168","author":"X Jiao","year":"2002","unstructured":"Jiao, X. et al. Dendritic cells are host cells for mycobacteria in vivo that trigger innate and acquired immunity. J. Immunol. 168, 1294\u20131301 (2002).","journal-title":"J. Immunol."},{"key":"278_CR69","doi-asserted-by":"publisher","first-page":"6883","DOI":"10.1128\/IAI.68.12.6883-6890.2000","volume":"68","author":"S Tsuji","year":"2000","unstructured":"Tsuji, S. et al. Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Gu\u00e9rin: involvement of toll-like receptors. Infect. Immun. 68, 6883\u20136890 (2000).","journal-title":"Infect. Immun."},{"key":"278_CR70","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.cyto.2007.11.020","volume":"41","author":"D Dowling","year":"2008","unstructured":"Dowling, D., Hamilton, C. M. & O\u2019Neill, S. M. A comparative analysis of cytokine responses, cell surface marker expression and MAPKs in DCs matured with LPS compared with a panel of TLR ligands. Cytokine 41, 254\u2013262 (2008).","journal-title":"Cytokine"},{"key":"278_CR71","doi-asserted-by":"publisher","first-page":"405310","DOI":"10.1155\/2011\/405310","volume":"2011","author":"J Kleinnijenhuis","year":"2011","unstructured":"Kleinnijenhuis, J., Oosting, M., Joosten, L. A., Netea, M. G. & Van Crevel, R. Innate immune recognition of Mycobacterium tuberculosis. Clin. Dev. Immunol. 2011, 405310 (2011).","journal-title":"Clin. Dev. Immunol."},{"key":"278_CR72","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/jnci\/52.1.95","volume":"52","author":"I Azuma","year":"1974","unstructured":"Azuma, I., Ribi, E. E., Meyer, T. J. & Zbar, B. Biologically active components from mycobacterial cell walls. I. Isolation and composition of cell wall skeleton and component P3. J. Natl. Cancer Inst. 52, 95\u2013101 (1974).","journal-title":"J. Natl. Cancer Inst."},{"key":"278_CR73","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/S1367-5931(97)80055-5","volume":"1","author":"D Chatterjee","year":"1997","unstructured":"Chatterjee, D. The mycobacterial cell wall: structure, biosynthesis and sites of drug action. Curr. Opin. Chem. Biol. 1, 579\u2013588 (1997).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"278_CR74","doi-asserted-by":"publisher","first-page":"4425","DOI":"10.4049\/jimmunol.172.7.4425","volume":"172","author":"VJ Quesniaux","year":"2004","unstructured":"Quesniaux, V. J. et al. Toll-like receptor 2 (TLR2)-dependent-positive and TLR2-independent-negative regulation of proinflammatory cytokines by mycobacterial lipomannans. J. Immunol. 172, 4425\u20134434 (2004).","journal-title":"J. Immunol."},{"key":"278_CR75","doi-asserted-by":"publisher","first-page":"20961","DOI":"10.1074\/jbc.M411379200","volume":"280","author":"Y Bulut","year":"2005","unstructured":"Bulut, Y. et al. Mycobacterium tuberculosis heat shock proteins use diverse Toll-like receptor pathways to activate pro-inflammatory signals. J. Biol. Chem. 280, 20961\u201320967 (2005).","journal-title":"J. Biol. Chem."},{"key":"278_CR76","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/j.1365-2567.2012.03575.x","volume":"136","author":"K Kim","year":"2012","unstructured":"Kim, K. et al. Mycobacterium tuberculosis Rv0652 stimulates production of tumour necrosis factor and monocytes chemoattractant protein-1 in macrophages through the Toll-like receptor 4 pathway. Immunology 136, 231\u2013240 (2012).","journal-title":"Immunology"},{"key":"278_CR77","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1128\/IAI.74.5.2686-2696.2006","volume":"74","author":"SB Jung","year":"2006","unstructured":"Jung, S. B. et al. The mycobacterial 38-kilodalton glycolipoprotein antigen activates the mitogen-activated protein kinase pathway and release of proinflammatory cytokines through Toll-like receptors 2 and 4 in human monocytes. Infect. Immun. 74, 2686\u20132696 (2006).","journal-title":"Infect. Immun."},{"key":"278_CR78","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1177\/1753425919879997","volume":"26","author":"J Li","year":"2020","unstructured":"Li, J. et al. Unmethylated CpG motif-containing genomic DNA fragment of Bacillus calmette-guerin promotes macrophage functions through TLR9-mediated activation of NF-\u03baB and MAPKs signaling pathways. Innate Immun. 26, 183\u2013203 (2020).","journal-title":"Innate Immun."},{"key":"278_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7883\/yoken.52.1","volume":"52","author":"T Tokunaga","year":"1999","unstructured":"Tokunaga, T., Yamamoto, T. & Yamamoto, S. How BCG led to the discovery of immunostimulatory DNA. Jpn. J. Infect. Dis. 52, 1\u201311 (1999).","journal-title":"Jpn. J. Infect. Dis."},{"key":"278_CR80","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/ni1112","volume":"5","author":"A Iwasaki","year":"2004","unstructured":"Iwasaki, A. & Medzhitov, R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5, 987\u2013995 (2004).","journal-title":"Nat. Immunol."},{"key":"278_CR81","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.imbio.2006.05.004","volume":"211","author":"F von Meyenn","year":"2006","unstructured":"von Meyenn, F. et al. Toll-like receptor 9 contributes to recognition of Mycobacterium bovis Bacillus Calmette-Gu\u00e9rin by Flt3-ligand generated dendritic cells. Immunobiology 211, 557\u2013565 (2006).","journal-title":"Immunobiology"},{"key":"278_CR82","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1084\/jem.20051782","volume":"202","author":"A Bafica","year":"2005","unstructured":"Bafica, A. et al. TLR9 regulates Th1 responses and cooperates with TLR2 in mediating optimal resistance to Mycobacterium tuberculosis. J. Exp. Med. 202, 1715\u20131724 (2005).","journal-title":"J. Exp. Med."},{"key":"278_CR83","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1189\/jlb.0105037","volume":"78","author":"MC Gagliardi","year":"2005","unstructured":"Gagliardi, M. C. et al. Mycobacterium bovis Bacillus Calmette-Guerin infects DC-SIGN- dendritic cell and causes the inhibition of IL-12 and the enhancement of IL-10 production. J. Leukoc. Biol. 78, 106\u2013113 (2005).","journal-title":"J. Leukoc. Biol."},{"key":"278_CR84","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/nm.2087","volume":"16","author":"TB Clarke","year":"2010","unstructured":"Clarke, T. B. et al. Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity. Nat. Med. 16, 228\u2013231 (2010).","journal-title":"Nat. Med."},{"key":"278_CR85","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.smim.2013.04.006","volume":"25","author":"SH Kaufmann","year":"2013","unstructured":"Kaufmann, S. H. Tuberculosis vaccines: time to think about the next generation. Semin. Immunol. 25, 172\u2013181 (2013).","journal-title":"Semin. Immunol."},{"key":"278_CR86","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005206","volume":"11","author":"VP Bollampalli","year":"2015","unstructured":"Bollampalli, V. P. et al. BCG skin infection triggers IL-1R-MyD88-dependent migration of EpCAMlow CD11bhigh skin dendritic cells to draining lymph node during CD4\u2009+\u2009T-cell priming. PLoS Pathog. 11, e1005206 (2015).","journal-title":"PLoS Pathog."},{"key":"278_CR87","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/JLB.4A0917-363RR","volume":"103","author":"E Bizzell","year":"2018","unstructured":"Bizzell, E. et al. Deletion of BCG Hip1 protease enhances dendritic cell and CD4 T cell responses. J. Leukoc. Biol. 103, 739\u2013748 (2018).","journal-title":"J. Leukoc. Biol."},{"key":"278_CR88","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.molimm.2019.02.021","volume":"109","author":"H Su","year":"2019","unstructured":"Su, H., Peng, B., Zhang, Z., Liu, Z. & Zhang, Z. The Mycobacterium tuberculosis glycoprotein Rv1016c protein inhibits dendritic cell maturation, and impairs Th1 \/Th17 responses during mycobacteria infection. Mol. Immunol. 109, 58\u201370 (2019).","journal-title":"Mol. Immunol."},{"key":"278_CR89","doi-asserted-by":"publisher","first-page":"7948","DOI":"10.4049\/jimmunol.181.11.7948","volume":"181","author":"S Bertholet","year":"2008","unstructured":"Bertholet, S. et al. Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis. J. Immunol. 181, 7948\u20137957 (2008).","journal-title":"J. Immunol."},{"key":"278_CR90","doi-asserted-by":"publisher","unstructured":"Andersen, P. & Kaufmann, S. H. Novel vaccination strategies against tuberculosis. Cold Spring Harb. Perspect. Med. 4. https:\/\/doi.org\/10.1101\/cshperspect.a018523 (2014).","DOI":"10.1101\/cshperspect.a018523"},{"key":"278_CR91","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1016\/S0140-6736(03)13491-5","volume":"361","author":"M Rossouw","year":"2003","unstructured":"Rossouw, M., Nel, H. J., Cooke, G. S., van Helden, P. D. & Hoal, E. G. Association between tuberculosis and a polymorphic NFkappaB binding site in the interferon gamma gene. Lancet (Lond., Engl.) 361, 1871\u20131872 (2003).","journal-title":"Lancet (Lond., Engl.)"},{"key":"278_CR92","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/eji.200737905","volume":"38","author":"C Morel","year":"2008","unstructured":"Morel, C. et al. Mycobacterium bovis BCG-infected neutrophils and dendritic cells cooperate to induce specific T cell responses in humans and mice. Eur. J. Immunol. 38, 437\u2013447 (2008).","journal-title":"Eur. J. Immunol."},{"key":"278_CR93","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1196\/annals.1358.010","volume":"1062","author":"WA Hanekom","year":"2005","unstructured":"Hanekom, W. A. The immune response to BCG vaccination of newborns. Ann. N. Y. Acad. Sci. 1062, 69\u201378 (2005).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"278_CR94","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1093\/infdis\/jis941","volume":"207","author":"AP Soares","year":"2013","unstructured":"Soares, A. P. et al. Longitudinal changes in CD4(\u2009+\u2009) T-cell memory responses induced by BCG vaccination of newborns. J. Infect. Dis. 207, 1084\u20131094 (2013). 92.","journal-title":"J. Infect. Dis."},{"key":"278_CR95","doi-asserted-by":"publisher","first-page":"5647","DOI":"10.4049\/jimmunol.177.8.5647","volume":"177","author":"RA Murray","year":"2006","unstructured":"Murray, R. A. et al. Bacillus Calmette Guerin vaccination of human newborns induces a specific, functional CD8\u2009+\u2009T cell response. J. Immunol. 177, 5647\u20135651 (2006). 93.","journal-title":"J. Immunol."},{"key":"278_CR96","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1146\/annurev.iy.07.040189.001045","volume":"7","author":"TR Mosmann","year":"1989","unstructured":"Mosmann, T. R. & Coffman, R. L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7, 145\u2013173 (1989).","journal-title":"Annu. Rev. Immunol."},{"key":"278_CR97","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41577-018-0028-0","volume":"18","author":"H Li","year":"2018","unstructured":"Li, H. & Javid, B. Antibodies and tuberculosis: finally coming of age?. Nat. Rev. Immunol. 18, 591\u2013596 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"278_CR98","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003472","volume":"9","author":"L Kozakiewicz","year":"2013","unstructured":"Kozakiewicz, L. et al. B cells regulate neutrophilia during Mycobacterium tuberculosis infection and BCG vaccination by modulating the interleukin-17 response. PLoS Pathog. 9, e1003472 (2013).","journal-title":"PLoS Pathog."},{"key":"278_CR99","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0051381","volume":"7","author":"I Sebina","year":"2012","unstructured":"Sebina, I. et al. Long-lived memory B-cell responses following BCG vaccination. PloS ONE 7, e51381 (2012).","journal-title":"PloS ONE"},{"key":"278_CR100","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1093\/infdis\/jiw141","volume":"214","author":"T Chen","year":"2016","unstructured":"Chen, T. et al. Association of human antibodies to arabinomannan with enhanced mycobacterial opsonophagocytosis and intracellular growth reduction. J. Infect. Dis. 214, 300\u2013310 (2016).","journal-title":"J. Infect. Dis."},{"key":"278_CR101","first-page":"706","volume":"6","author":"C S\u00e1nchez-Rodr\u00edguez","year":"2002","unstructured":"S\u00e1nchez-Rodr\u00edguez, C. et al. An IgG antibody response to the antigen 85 complex is associated with good outcome in Mexican Totonaca Indians with pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 6, 706\u2013712 (2002).","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"278_CR102","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/0035-9203(92)90192-F","volume":"86","author":"AM Costello","year":"1992","unstructured":"Costello, A. M. et al. Does antibody to mycobacterial antigens, including lipoarabinomannan, limit dissemination in childhood tuberculosis? Trans. R. Soc. Trop. Med. Hyg. 86, 686\u2013692 (1992).","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"278_CR103","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.cell.2016.08.072","volume":"167","author":"LL Lu","year":"2016","unstructured":"Lu, L. L. et al. A functional role for antibodies in tuberculosis. Cell 167, 433\u2013443 e414 (2016).","journal-title":"Cell"},{"key":"278_CR104","doi-asserted-by":"publisher","unstructured":"Uranga, S., Marinova, D., Martin, C. & Aguilo, N. Protective efficacy and pulmonary immune response following subcutaneous and intranasal BCG administration in mice. J. Vis. Exp. https:\/\/doi.org\/10.3791\/54440 (2016).","DOI":"10.3791\/54440"},{"key":"278_CR105","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s00018-018-2976-8","volume":"76","author":"IS Hansen","year":"2019","unstructured":"Hansen, I. S., Baeten, D. L. P. & den Dunnen, J. The inflammatory function of human IgA. Cell Mol. Life Sci. 76, 1041\u20131055 (2019).","journal-title":"Cell Mol. Life Sci."},{"key":"278_CR106","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nri820","volume":"2","author":"RM Welsh","year":"2002","unstructured":"Welsh, R. M. & Selin, L. K. No one is naive: the significance of heterologous T-cell immunity. Nat. Rev. Immunol. 2, 417\u2013426 (2002).","journal-title":"Nat. Rev. Immunol."},{"key":"278_CR107","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.chom.2011.04.006","volume":"9","author":"MG Netea","year":"2011","unstructured":"Netea, M. G., Quintin, J. & van der Meer, J. W. Trained immunity: a memory for innate host defense. Cell Host Microbe 9, 355\u2013361 (2011).","journal-title":"Cell Host Microbe"},{"key":"278_CR108","doi-asserted-by":"publisher","first-page":"17537","DOI":"10.1073\/pnas.1202870109","volume":"109","author":"J Kleinnijenhuis","year":"2012","unstructured":"Kleinnijenhuis, J. et al. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc. Natl. Acad. Sci. USA 109, 17537\u201317542 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"278_CR109","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0014066","volume":"5","author":"Y Djuardi","year":"2010","unstructured":"Djuardi, Y., Sartono, E., Wibowo, H., Supali, T. & Yazdanbakhsh, M. A longitudinal study of BCG vaccination in early childhood: the development of innate and adaptive immune responses. PloS ONE 5, e14066 (2010).","journal-title":"PloS ONE"},{"key":"278_CR110","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1128\/JVI.02393-08","volume":"83","author":"KS Mathurin","year":"2009","unstructured":"Mathurin, K. S., Martens, G. W., Kornfeld, H. & Welsh, R. M. CD4 T-cell-mediated heterologous immunity between mycobacteria and poxviruses. J. Virol. 83, 3528\u20133539 (2009).","journal-title":"J. Virol."},{"key":"278_CR111","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1159\/000355628","volume":"6","author":"J Kleinnijenhuis","year":"2014","unstructured":"Kleinnijenhuis, J. et al. Long-lasting effects of BCG vaccination on both heterologous Th1\/Th17 responses and innate trained immunity. J. Innate Immun. 6, 152\u2013158 (2014).","journal-title":"J. Innate Immun."},{"key":"278_CR112","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1002\/1521-4141(2002010)32:10<2807::AID-IMMU2807>3.0.CO;2-0","volume":"32","author":"RE Berg","year":"2002","unstructured":"Berg, R. E., Cordes, C. J. & Forman, J. Contribution of CD8\u2009+\u2009T cells to innate immunity: IFN-gamma secretion induced by IL-12 and IL-18. Eur. J. Immunol. 32, 2807\u20132816 (2002).","journal-title":"Eur. J. Immunol."},{"key":"278_CR113","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1084\/jem.20031051","volume":"198","author":"RE Berg","year":"2003","unstructured":"Berg, R. E., Crossley, E., Murray, S. & Forman, J. Memory CD8\u2009+\u2009T cells provide innate immune protection against Listeria monocytogenes in the absence of cognate antigen. J. Exp. Med. 198, 1583\u20131593 (2003).","journal-title":"J. Exp. Med."},{"key":"278_CR114","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.4049\/jimmunol.166.2.1097","volume":"166","author":"G Lertmemongkolchai","year":"2001","unstructured":"Lertmemongkolchai, G., Cai, G., Hunter, C. A. & Bancroft, G. J. Bystander activation of CD8\u2009+\u2009T cells contributes to the rapid production of IFN-gamma in response to bacterial pathogens. J. Immunol. 166, 1097\u20131105 (2001).","journal-title":"J. Immunol."},{"key":"278_CR115","doi-asserted-by":"publisher","first-page":"179","DOI":"10.4161\/psb.1.4.3221","volume":"1","author":"U Conrath","year":"2006","unstructured":"Conrath, U. Systemic acquired resistance. Plant Signal. Behav. 1, 179\u2013184 (2006).","journal-title":"Plant Signal. Behav."},{"key":"278_CR116","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.0030026","volume":"3","author":"LN Pham","year":"2007","unstructured":"Pham, L. N., Dionne, M. S., Shirasu-Hiza, M. & Schneider, D. S. A specific primed immune response in Drosophila is dependent on phagocytes. PLoS Pathog. 3, e26 (2007).","journal-title":"PLoS Pathog."},{"key":"278_CR117","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1126\/science.1190689","volume":"329","author":"J Rodrigues","year":"2010","unstructured":"Rodrigues, J., Brayner, F. A., Alves, L. C., Dixit, R. & Barillas-Mury, C. Hemocyte differentiation mediates innate immune memory in Anopheles gambiae mosquitoes. Science 329, 1353\u20131355 (2010).","journal-title":"Science"},{"key":"278_CR118","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/nature07665","volume":"457","author":"JC Sun","year":"2009","unstructured":"Sun, J. C., Beilke, J. N. & Lanier, L. L. Adaptive immune features of natural killer cells. Nature 457, 557\u2013561 (2009).","journal-title":"Nature"},{"key":"278_CR119","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.chom.2012.06.006","volume":"12","author":"J Quintin","year":"2012","unstructured":"Quintin, J. et al. Candida albicans infection affords protection against reinfection via functional reprogramming of monocytes. Cell Host Microbe 12, 223\u2013232 (2012).","journal-title":"Cell Host Microbe"},{"key":"278_CR120","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/trstmh\/tru168","volume":"109","author":"J Kleinnijenhuis","year":"2015","unstructured":"Kleinnijenhuis, J., van Crevel, R. & Netea, M. G. Trained immunity: consequences for the heterologous effects of BCG vaccination. Trans. R. Soc. Tropical Med. Hyg. 109, 29\u201335 (2015).","journal-title":"Trans. R. Soc. Tropical Med. Hyg."},{"key":"278_CR121","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.3389\/fimmu.2019.02806","volume":"10","author":"C Covi\u00e1n","year":"2019","unstructured":"Covi\u00e1n, C. et al. BCG-induced cross-protection and development of trained immunity: implication for vaccine design. Front. Immunol. 10, 2806 (2019).","journal-title":"Front. Immunol."},{"key":"278_CR122","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1182\/blood-2007-08-106443","volume":"111","author":"H Wen","year":"2008","unstructured":"Wen, H., Dou, Y., Hogaboam, C. M. & Kunkel, S. L. Epigenetic regulation of dendritic cell-derived interleukin-12 facilitates immunosuppression after a severe innate immune response. Blood 111, 1797\u20131804 (2008).","journal-title":"Blood"},{"key":"278_CR123","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.clim.2008.08.015","volume":"130","author":"SL Foster","year":"2009","unstructured":"Foster, S. L. & Medzhitov, R. Gene-specific control of the TLR-induced inflammatory response. Clin. Immunol. 130, 7\u201315 (2009).","journal-title":"Clin. Immunol."},{"key":"278_CR124","doi-asserted-by":"publisher","first-page":"679804","DOI":"10.1155\/2013\/679804","volume":"2013","author":"C Do\u00f1as","year":"2013","unstructured":"Do\u00f1as, C. et al. Trichostatin A promotes the generation and suppressive functions of regulatory T cells. Clin. Dev. Immunol. 2013, 679804 (2013).","journal-title":"Clin. Dev. Immunol."},{"key":"278_CR125","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41577-019-0151-6","volume":"19","author":"Q Zhang","year":"2019","unstructured":"Zhang, Q. & Cao, X. Epigenetic regulation of the innate immune response to infection. Nat. Rev. Immunol. 19, 417\u2013432 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"278_CR126","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1189\/jlb.4MA0215-059R","volume":"98","author":"RJ Arts","year":"2015","unstructured":"Arts, R. J. et al. Long-term in vitro and in vivo effects of \u03b3-irradiated BCG on innate and adaptive immunity. J. Leukoc. Biol. 98, 995\u20131001 (2015).","journal-title":"J. Leukoc. Biol."},{"key":"278_CR127","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.chom.2017.12.010","volume":"23","author":"RJW Arts","year":"2018","unstructured":"Arts, R. J. W. et al. BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity. Cell Host Microbe 23, 89\u2013100 e105 (2018).","journal-title":"Cell Host Microbe"},{"key":"278_CR128","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.4049\/jimmunol.1202611","volume":"190","author":"DC Ifrim","year":"2013","unstructured":"Ifrim, D. C. et al. Candida albicans primes TLR cytokine responses through a Dectin-1\/Raf-1-mediated pathway. J. Immunol. 190, 4129\u20134135 (2013).","journal-title":"J. Immunol."},{"key":"278_CR129","doi-asserted-by":"publisher","first-page":"1250684","DOI":"10.1126\/science.1250684","volume":"345","author":"SC Cheng","year":"2014","unstructured":"Cheng, S. C. et al. mTOR- and HIF-1\u03b1-mediated aerobic glycolysis as metabolic basis for trained immunity. Science 345, 1250684 (2014).","journal-title":"Science"},{"key":"278_CR130","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.cmet.2016.10.008","volume":"24","author":"RJ Arts","year":"2016","unstructured":"Arts, R. J. et al. Glutaminolysis and fumarate accumulation integrate immunometabolic and epigenetic programs in trained immunity. Cell Metab. 24, 807\u2013819 (2016).","journal-title":"Cell Metab."},{"key":"278_CR131","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.celrep.2018.09.092","volume":"25","author":"P Saz-Leal","year":"2018","unstructured":"Saz-Leal, P. et al. Targeting SHIP-1 in myeloid cells enhances trained immunity and boosts response to infection. Cell Rep. 25, 1118\u20131126 (2018).","journal-title":"Cell Rep."},{"key":"278_CR132","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.cmet.2018.09.003","volume":"29","author":"J Dom\u00ednguez-Andr\u00e9s","year":"2019","unstructured":"Dom\u00ednguez-Andr\u00e9s, J. et al. The itaconate pathway is a central regulatory node linking innate immune tolerance and trained immunity. Cell Metab. 29, 211\u2013220. e215 (2019).","journal-title":"Cell Metab."},{"key":"278_CR133","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.cell.2017.11.025","volume":"172","author":"S Bekkering","year":"2018","unstructured":"Bekkering, S. et al. Metabolic induction of trained immunity through the mevalonate pathway. Cell 172, 135\u2013146. e139 (2018).","journal-title":"Cell"},{"key":"278_CR134","doi-asserted-by":"publisher","first-page":"1251086","DOI":"10.1126\/science.1251086","volume":"345","author":"S Saeed","year":"2014","unstructured":"Saeed, S. et al. Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity. Science 345, 1251086 (2014).","journal-title":"Science"},{"key":"278_CR135","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.cell.2017.12.031","volume":"172","author":"E Kaufmann","year":"2018","unstructured":"Kaufmann, E. et al. BCG educates hematopoietic stem cells to generate protective innate immunity against tuberculosis. Cell 172, 176\u2013190. e119 (2018).","journal-title":"Cell"},{"key":"278_CR136","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212751","volume":"14","author":"M Guerra-Maupome","year":"2019","unstructured":"Guerra-Maupome, M., Vang, D. X. & McGill, J. L. Aerosol vaccination with Bacille Calmette-Guerin induces a trained innate immune phenotype in calves. PloS ONE 14, e0212751 (2019).","journal-title":"PloS ONE"},{"key":"278_CR137","doi-asserted-by":"publisher","first-page":"869","DOI":"10.3389\/fimmu.2018.00869","volume":"9","author":"LCJ de Bree","year":"2018","unstructured":"de Bree, L. C. J. et al. Bacillus Calmette-Gu\u00e9rin-induced trained immunity is not protective for experimental influenza A\/Anhui\/1\/2013 (H7N9) infection in mice. Front. Immunol. 9, 869 (2018).","journal-title":"Front. Immunol."},{"key":"278_CR138","unstructured":"WHO. Bacille Calmette-Guerin (BCG) vaccination and COVID-19. www.who.int\/news-room\/commentaries\/detail\/bacille-calmette-gu%C3%A9rin-(bcg)-vaccination-and-covid-19 (2020)."},{"key":"278_CR139","doi-asserted-by":"publisher","DOI":"10.1007\/s11934-018-0852-6","volume":"19","author":"TK Nykopp","year":"2018","unstructured":"Nykopp, T. K., Batista da Costa, J., Mannas, M. & Black, P. C. Current Clinical Trials in non-muscle invasive bladder cancer. Curr. Urol. Rep. 19, 101 (2018).","journal-title":"Curr. Urol. Rep."},{"key":"278_CR140","first-page":"65","volume":"7","author":"O Fuge","year":"2015","unstructured":"Fuge, O., Vasdev, N., Allchorne, P. & Green, J. S. Immunotherapy for bladder cancer. Res. Rep. Urol. 7, 65\u201379 (2015).","journal-title":"Res. Rep. Urol."},{"key":"278_CR141","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1016\/j.juro.2007.09.003","volume":"178","author":"MC Hall","year":"2007","unstructured":"Hall, M. C. et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J. Urol. 178, 2314\u20132330 (2007).","journal-title":"J. Urol."},{"key":"278_CR142","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-6304-y","volume":"19","author":"J Zhang","year":"2019","unstructured":"Zhang, J. et al. Management of non-muscle-invasive bladder cancer: quality of clinical practice guidelines and variations in recommendations. BMC Cancer 19, 1054 (2019).","journal-title":"BMC Cancer"},{"key":"278_CR143","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.eururo.2012.08.061","volume":"63","author":"M Burger","year":"2013","unstructured":"Burger, M. et al. ICUD-EAU International Consultation on Bladder Cancer 2012: non-muscle-invasive urothelial carcinoma of the bladder. Eur. Urol. 63, 36\u201344 (2013).","journal-title":"Eur. Urol."},{"key":"278_CR144","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/nrurol.2015.58","volume":"12","author":"AM Kamat","year":"2015","unstructured":"Kamat, A. M. et al. Expert consensus document: consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer. Nat. Rev. Urol. 12, 225\u2013235 (2015).","journal-title":"Nat. Rev. Urol."},{"key":"278_CR145","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","volume":"71","author":"M Babjuk","year":"2017","unstructured":"Babjuk, M. et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur. Urol. 71, 447\u2013461 (2017).","journal-title":"Eur. Urol."},{"key":"278_CR146","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0022-5347(17)39365-5","volume":"144","author":"A B\u00f6hle","year":"1990","unstructured":"B\u00f6hle, A., Gerdes, J., Ulmer, A. J., Hofstetter, A. G. & Flad, H. D. Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J. Urol. 144, 53\u201358 (1990).","journal-title":"J. Urol."},{"key":"278_CR147","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1172\/JCI114434","volume":"85","author":"LR Kavoussi","year":"1990","unstructured":"Kavoussi, L. R., Brown, E. J., Ritchey, J. K. & Ratliff, T. L. Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response. J. Clin. Investig. 85, 62\u201367 (1990).","journal-title":"J. Clin. Investig."},{"key":"278_CR148","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S1286-4579(00)00268-9","volume":"2","author":"WP Maksymowych","year":"2000","unstructured":"Maksymowych, W. P. & Kane, K. P. Bacterial modulation of antigen processing and presentation. Microbes Infect. 2, 199\u2013211 (2000).","journal-title":"Microbes Infect."},{"key":"278_CR149","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/BF01741603","volume":"33","author":"EC De Boer","year":"1991","unstructured":"De Boer, E. C. et al. Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Gu\u00e9rin. Cancer Immunol. Immunother. 33, 411\u2013416 (1991).","journal-title":"Cancer Immunol. Immunother."},{"key":"278_CR150","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/S0022-5347(17)39713-6","volume":"144","author":"S Prescott","year":"1990","unstructured":"Prescott, S., James, K., Hargreave, T. B., Chisholm, G. D. & Smyth, J. F. Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J. Urol. 144, 1248\u20131251 (1990).","journal-title":"J. Urol."},{"key":"278_CR151","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1046\/j.1365-2249.2003.02071.x","volume":"131","author":"R Nadler","year":"2003","unstructured":"Nadler, R. et al. Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Gu\u00e9rin (BCG) mediated antitumour activity. Clin. Exp. Immunol. 131, 206\u2013216 (2003).","journal-title":"Clin. Exp. Immunol."},{"key":"278_CR152","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/BF00296835","volume":"21","author":"TM de Reijke","year":"1993","unstructured":"de Reijke, T. M. et al. Cytokine production by the human bladder carcinoma cell line T24 in the presence of bacillus Calmette-Guerin (BCG). Urol. Res. 21, 349\u2013352 (1993).","journal-title":"Urol. Res."},{"key":"278_CR153","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/BF00941903","volume":"25","author":"EC de Boer","year":"1997","unstructured":"de Boer, E. C. et al. Role of interleukin-8 in onset of the immune response in intravesical BCG therapy for superficial bladder cancer. Urol. Res. 25, 31\u201334 (1997).","journal-title":"Urol. Res."},{"key":"278_CR154","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/BF01741551","volume":"34","author":"EC De Boer","year":"1992","unstructured":"De Boer, E. C. et al. Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Gu\u00e9rin in superficial bladder cancer. Cancer Immunol. Immunother. 34, 306\u2013312 (1992).","journal-title":"Cancer Immunol. Immunother."},{"key":"278_CR155","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0022-5347(01)67113-1","volume":"154","author":"K Esuvaranathan","year":"1995","unstructured":"Esuvaranathan, K. et al. Interleukin-6 production by bladder tumors is upregulated by BCG immunotherapy. J. Urol. 154, 572\u2013575 (1995).","journal-title":"J. Urol."},{"key":"278_CR156","doi-asserted-by":"publisher","first-page":"39916","DOI":"10.18632\/oncotarget.9537","volume":"7","author":"R Pichler","year":"2016","unstructured":"Pichler, R. et al. Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Gu\u00e9rin therapy in bladder cancer. Oncotarget 7, 39916\u201339930 (2016).","journal-title":"Oncotarget"},{"key":"278_CR157","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/S0022-5347(17)45922-2","volume":"135","author":"JM Lage","year":"1986","unstructured":"Lage, J. M., Bauer, W. C., Kelley, D. R., Ratliff, T. L. & Catalona, W. J. Histological parameters and pitfalls in the interpretation of bladder biopsies in bacillus Calmette-Guerin treatment of superficial bladder cancer. J. Urol. 135, 916\u2013919 (1986).","journal-title":"J. Urol."},{"key":"278_CR158","first-page":"179","volume":"9","author":"A Alexandroff","year":"1996","unstructured":"Alexandroff, A., Jackson, A., Skibinska, A. & James, K. Production of IL-5, a classical T(H)2 cytokine, following bacillus Calmette guerin immunotherapy of bladder cancer. Int. J. Oncol. 9, 179\u2013182 (1996).","journal-title":"Int. J. Oncol."},{"key":"278_CR159","doi-asserted-by":"publisher","first-page":"4246","DOI":"10.4049\/jimmunol.163.8.4246","volume":"163","author":"MA O\u2019Donnell","year":"1999","unstructured":"O\u2019Donnell, M. A. et al. Role of IL-12 in the induction and potentiation of IFN-gamma in response to bacillus Calmette-Gu\u00e9rin. J. Immunol. 163, 4246\u20134252 (1999).","journal-title":"J. Immunol."},{"key":"278_CR160","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1365-2249.1995.tb05560.x","volume":"99","author":"AM Jackson","year":"1995","unstructured":"Jackson, A. M. et al. Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy. Clin. Exp. Immunol. 99, 369\u2013375 (1995).","journal-title":"Clin. Exp. Immunol."},{"key":"278_CR161","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1159\/000087163","volume":"75","author":"M Eto","year":"2005","unstructured":"Eto, M. et al. Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-gu\u00e9rin for superficial bladder tumors. Urol. Int. 75, 114\u2013118 (2005).","journal-title":"Urol. Int."},{"key":"278_CR162","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/j.1365-2249.2006.03288.x","volume":"147","author":"Y Luo","year":"2007","unstructured":"Luo, Y., Chen, X. & O\u2019Donnell, M. A. Mycobacterium bovis bacillus Calmette-Gu\u00e9rin (BCG) induces human CC- and CXC-chemokines in vitro and in vivo. Clin. Exp. Immunol. 147, 370\u2013378 (2007).","journal-title":"Clin. Exp. Immunol."},{"key":"278_CR163","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/BF00294021","volume":"19","author":"EC de Boer","year":"1991","unstructured":"de Boer, E. C. et al. Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis. Urol. Res. 19, 45\u201350 (1991).","journal-title":"Urol. Res."},{"key":"278_CR164","doi-asserted-by":"publisher","first-page":"3386","DOI":"10.1158\/0008-5472.CAN-04-0374","volume":"64","author":"AT Ludwig","year":"2004","unstructured":"Ludwig, A. T. et al. Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Gu\u00e9rin-induced antitumor activity. Cancer Res. 64, 3386\u20133390 (2004).","journal-title":"Cancer Res."},{"key":"278_CR165","doi-asserted-by":"publisher","first-page":"8250","DOI":"10.1158\/0008-5472.CAN-06-1416","volume":"66","author":"H Suttmann","year":"2006","unstructured":"Suttmann, H. et al. Neutrophil granulocytes are required for effective Bacillus Calmette-Gu\u00e9rin immunotherapy of bladder cancer and orchestrate local immune responses. Cancer Res. 66, 8250\u20138257 (2006).","journal-title":"Cancer Res."},{"key":"278_CR166","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/S0022-5347(17)37668-1","volume":"147","author":"S Prescott","year":"1992","unstructured":"Prescott, S., James, K., Hargreave, T. B., Chisholm, G. D. & Smyth, J. F. Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J. Urol. 147, 1636\u20131642 (1992).","journal-title":"J. Urol."},{"key":"278_CR167","doi-asserted-by":"publisher","first-page":"4647","DOI":"10.1128\/IAI.71.8.4647-4656.2003","volume":"71","author":"H Suttmann","year":"2003","unstructured":"Suttmann, H., Lehan, N., B\u00f6hle, A. & Brandau, S. Stimulation of neutrophil granulocytes with Mycobacterium bovis bacillus Calmette-Gu\u00e9rin induces changes in phenotype and gene expression and inhibits spontaneous apoptosis. Infect. Immun. 71, 4647\u20134656 (2003).","journal-title":"Infect. Immun."},{"key":"278_CR168","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0022-5347(17)43909-7","volume":"137","author":"TL Ratliff","year":"1987","unstructured":"Ratliff, T. L., Gillen, D. & Catalona, W. J. Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J. Urol. 137, 155\u2013158 (1987).","journal-title":"J. Urol."},{"key":"278_CR169","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/S0090-4295(01)00921-9","volume":"57","author":"F Saint","year":"2001","unstructured":"Saint, F. et al. Leukocyturia as a predictor of tolerance and efficacy of intravesical BCG maintenance therapy for superficial bladder cancer. Urology 57, 617\u2013621 (2001).","journal-title":"Urology"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-020-00278-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-020-00278-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-020-00278-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T07:09:47Z","timestamp":1674889787000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-020-00278-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,25]]},"references-count":169,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["278"],"URL":"https:\/\/doi.org\/10.1038\/s41541-020-00278-0","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,25]]},"assertion":[{"value":"20 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14"}}